Novo Nordisk (NVO)
Invest in a Cure For Obesity
With a 42% price return since it was added to our portfolio in February 2014, Novo Nordisk's (NVO) capital appreciation has quite dwarfed its annual yield on cost of 1.4%. But that's to be expected from a company with as many great catalysts for growth on the horizon as Novo Nordisk. Here's what I wrote about Novo's current projects my latest Cabot Dividend Investor update, published last week:
"Novo Nordisk powered ahead this month on positive drug news. Last Wednesday, the company launched Saxenda, an anti-obesity drug, in the U.S., and said it would launch in other markets by the end of the year. In addition, the company has resubmitted Tresiba, a long-acting insulin, for approval in the U.S. after it was rejected in 2013. Novo Nordisk is partway through the new cardiovascular safety study the FDA requested at that time and says it now has enough interim data to resubmit the drug. Though there's no guarantee things will go better this time, Novo's decision to resubmit the drug after sharing interim results with regulators suggests the company has a good degree of confidence. Resubmissions are usually approved or rejected within a month. NVO is a Buy for annual income, dividend growth and capital appreciation."
If you've always thought dividend stocks were boring or just for "widows and orphans," today's huge universe of dividend-paying companies should be enough to make you think again.
|Novo Nordisk A/S
Denmark - Map
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55
Index Membership: N/A
Industry: Drug Manufacturers - Other
Full Time Employees: 39,062